トリプルネガティブ乳がん治療の世界市場（～2026年）

• 英文タイトル：Global Triple-Negative Breast Cancer Treatment Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY04900
• 出版社/出版日：QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、90ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料はトリプルネガティブ乳がん治療のグローバル市場について調査・分析したレポートです。種類別（アルキル化剤、植物製品、微生物製品、代謝拮抗剤、微小管安定剤）市場規模、用途別（病院薬局、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別トリプルネガティブ乳がん治療の競争状況、市場シェア
・世界のトリプルネガティブ乳がん治療市場：種類別市場規模 2015年-2020年（アルキル化剤、植物製品、微生物製品、代謝拮抗剤、微小管安定剤）
・世界のトリプルネガティブ乳がん治療市場：種類別市場規模予測 2021年-2026年（アルキル化剤、植物製品、微生物製品、代謝拮抗剤、微小管安定剤）
・世界のトリプルネガティブ乳がん治療市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局）
・世界のトリプルネガティブ乳がん治療市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局）
・北米のトリプルネガティブ乳がん治療市場分析：米国、カナダ
・ヨーロッパのトリプルネガティブ乳がん治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのトリプルネガティブ乳がん治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のトリプルネガティブ乳がん治療市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのトリプルネガティブ乳がん治療市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Celgene、Roche、Immunomedics GmbH、Merck & Co., Inc.、F. Hoffmann-La Roche Ltd、Eisai Co., Ltd
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Market Analysis and Insights: Global Triple-Negative Breast Cancer Treatment Market
The global Triple-Negative Breast Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Triple-Negative Breast Cancer Treatment Scope and Market Size
Triple-Negative Breast Cancer Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Triple-Negative Breast Cancer Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Celgene
Roche
Immunomedics GmbH
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
Eisai Co., Ltd
…

Market segment by Type, the product can be split into
Alkylating Agents
Plant Products
Microorganism Products
Antimetabolites
Microtubule Stablizing Agents
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Triple-Negative Breast Cancer Treatment Revenue
1.4 Market by Type
1.4.1 Global Triple-Negative Breast Cancer Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Alkylating Agents
1.4.3 Plant Products
1.4.4 Microorganism Products
1.4.5 Antimetabolites
1.4.6 Microtubule Stablizing Agents
1.5 Market by Application
1.5.1 Global Triple-Negative Breast Cancer Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Triple-Negative Breast Cancer Treatment Market Perspective (2015-2026)
2.2 Global Triple-Negative Breast Cancer Treatment Growth Trends by Regions
2.2.1 Triple-Negative Breast Cancer Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Triple-Negative Breast Cancer Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Triple-Negative Breast Cancer Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Triple-Negative Breast Cancer Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Triple-Negative Breast Cancer Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Triple-Negative Breast Cancer Treatment Players by Market Size
3.1.1 Global Top Triple-Negative Breast Cancer Treatment Players by Revenue (2015-2020)
3.1.2 Global Triple-Negative Breast Cancer Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Triple-Negative Breast Cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Triple-Negative Breast Cancer Treatment Market Concentration Ratio
3.2.1 Global Triple-Negative Breast Cancer Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Triple-Negative Breast Cancer Treatment Revenue in 2019
3.3 Triple-Negative Breast Cancer Treatment Key Players Head office and Area Served
3.4 Key Players Triple-Negative Breast Cancer Treatment Product Solution and Service
3.5 Date of Enter into Triple-Negative Breast Cancer Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Triple-Negative Breast Cancer Treatment Historic Market Size by Type (2015-2020)
4.2 Global Triple-Negative Breast Cancer Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020)
5.2 Global Triple-Negative Breast Cancer Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Triple-Negative Breast Cancer Treatment Market Size (2015-2020)
6.2 Triple-Negative Breast Cancer Treatment Key Players in North America (2019-2020)
6.3 North America Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020)
6.4 North America Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Triple-Negative Breast Cancer Treatment Market Size (2015-2020)
7.2 Triple-Negative Breast Cancer Treatment Key Players in Europe (2019-2020)
7.3 Europe Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020)
7.4 Europe Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020)

8 China
8.1 China Triple-Negative Breast Cancer Treatment Market Size (2015-2020)
8.2 Triple-Negative Breast Cancer Treatment Key Players in China (2019-2020)
8.3 China Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020)
8.4 China Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Triple-Negative Breast Cancer Treatment Market Size (2015-2020)
9.2 Triple-Negative Breast Cancer Treatment Key Players in Japan (2019-2020)
9.3 Japan Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020)
9.4 Japan Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Triple-Negative Breast Cancer Treatment Market Size (2015-2020)
10.2 Triple-Negative Breast Cancer Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020)

11 India
11.1 India Triple-Negative Breast Cancer Treatment Market Size (2015-2020)
11.2 Triple-Negative Breast Cancer Treatment Key Players in India (2019-2020)
11.3 India Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020)
11.4 India Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Triple-Negative Breast Cancer Treatment Market Size (2015-2020)
12.2 Triple-Negative Breast Cancer Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020)
12.4 Central & South America Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Celgene
13.1.1 Celgene Company Details
13.1.2 Celgene Business Overview
13.1.3 Celgene Triple-Negative Breast Cancer Treatment Introduction
13.1.4 Celgene Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020))
13.1.5 Celgene Recent Development
13.2 Roche
13.2.1 Roche Company Details
13.2.2 Roche Business Overview
13.2.3 Roche Triple-Negative Breast Cancer Treatment Introduction
13.2.4 Roche Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020)
13.2.5 Roche Recent Development
13.3 Immunomedics GmbH
13.3.1 Immunomedics GmbH Company Details
13.3.2 Immunomedics GmbH Business Overview
13.3.3 Immunomedics GmbH Triple-Negative Breast Cancer Treatment Introduction
13.3.4 Immunomedics GmbH Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020)
13.3.5 Immunomedics GmbH Recent Development
13.4 Merck & Co., Inc.
13.4.1 Merck & Co., Inc. Company Details
13.4.2 Merck & Co., Inc. Business Overview
13.4.3 Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Introduction
13.4.4 Merck & Co., Inc. Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020)
13.4.5 Merck & Co., Inc. Recent Development
13.5 F. Hoffmann-La Roche Ltd
13.5.1 F. Hoffmann-La Roche Ltd Company Details
13.5.2 F. Hoffmann-La Roche Ltd Business Overview
13.5.3 F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Introduction
13.5.4 F. Hoffmann-La Roche Ltd Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020)
13.5.5 F. Hoffmann-La Roche Ltd Recent Development
13.6 Eisai Co., Ltd
13.6.1 Eisai Co., Ltd Company Details
13.6.2 Eisai Co., Ltd Business Overview
13.6.3 Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Introduction
13.6.4 Eisai Co., Ltd Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020)
13.6.5 Eisai Co., Ltd Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Triple-Negative Breast Cancer Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Triple-Negative Breast Cancer Treatment Revenue
Table 3. Ranking of Global Top Triple-Negative Breast Cancer Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Triple-Negative Breast Cancer Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Alkylating Agents
Table 6. Key Players of Plant Products
Table 7. Key Players of Microorganism Products
Table 8. Key Players of Antimetabolites
Table 9. Key Players of Microtubule Stablizing Agents
Table 10. Global Triple-Negative Breast Cancer Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Triple-Negative Breast Cancer Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Triple-Negative Breast Cancer Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Triple-Negative Breast Cancer Treatment Market Share by Regions (2015-2020)
Table 14. Global Triple-Negative Breast Cancer Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Triple-Negative Breast Cancer Treatment Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Triple-Negative Breast Cancer Treatment Market Growth Strategy
Table 20. Main Points Interviewed from Key Triple-Negative Breast Cancer Treatment Players
Table 21. Global Triple-Negative Breast Cancer Treatment Revenue by Players (2015-2020) (Million US$)
Table 22. Global Triple-Negative Breast Cancer Treatment Market Share by Players (2015-2020)
Table 23. Global Top Triple-Negative Breast Cancer Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Triple-Negative Breast Cancer Treatment as of 2019)
Table 24. Global Triple-Negative Breast Cancer Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Triple-Negative Breast Cancer Treatment Product Solution and Service
Table 27. Date of Enter into Triple-Negative Breast Cancer Treatment Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 30. Global Triple-Negative Breast Cancer Treatment Market Size Share by Type (2015-2020)
Table 31. Global Triple-Negative Breast Cancer Treatment Revenue Market Share by Type (2021-2026)
Table 32. Global Triple-Negative Breast Cancer Treatment Market Size Share by Application (2015-2020)
Table 33. Global Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 34. Global Triple-Negative Breast Cancer Treatment Market Size Share by Application (2021-2026)
Table 35. North America Key Players Triple-Negative Breast Cancer Treatment Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Triple-Negative Breast Cancer Treatment Market Share (2019-2020)
Table 37. North America Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 38. North America Triple-Negative Breast Cancer Treatment Market Share by Type (2015-2020)
Table 39. North America Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 40. North America Triple-Negative Breast Cancer Treatment Market Share by Application (2015-2020)
Table 41. Europe Key Players Triple-Negative Breast Cancer Treatment Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Triple-Negative Breast Cancer Treatment Market Share (2019-2020)
Table 43. Europe Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Triple-Negative Breast Cancer Treatment Market Share by Type (2015-2020)
Table 45. Europe Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Triple-Negative Breast Cancer Treatment Market Share by Application (2015-2020)
Table 47. China Key Players Triple-Negative Breast Cancer Treatment Revenue (2019-2020) (Million US$)
Table 48. China Key Players Triple-Negative Breast Cancer Treatment Market Share (2019-2020)
Table 49. China Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 50. China Triple-Negative Breast Cancer Treatment Market Share by Type (2015-2020)
Table 51. China Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 52. China Triple-Negative Breast Cancer Treatment Market Share by Application (2015-2020)
Table 53. Japan Key Players Triple-Negative Breast Cancer Treatment Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Triple-Negative Breast Cancer Treatment Market Share (2019-2020)
Table 55. Japan Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Triple-Negative Breast Cancer Treatment Market Share by Type (2015-2020)
Table 57. Japan Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Triple-Negative Breast Cancer Treatment Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Triple-Negative Breast Cancer Treatment Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Triple-Negative Breast Cancer Treatment Market Share (2019-2020)
Table 61. Southeast Asia Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Triple-Negative Breast Cancer Treatment Market Share by Type (2015-2020)
Table 63. Southeast Asia Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Triple-Negative Breast Cancer Treatment Market Share by Application (2015-2020)
Table 65. India Key Players Triple-Negative Breast Cancer Treatment Revenue (2019-2020) (Million US$)
Table 66. India Key Players Triple-Negative Breast Cancer Treatment Market Share (2019-2020)
Table 67. India Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 68. India Triple-Negative Breast Cancer Treatment Market Share by Type (2015-2020)
Table 69. India Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 70. India Triple-Negative Breast Cancer Treatment Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Triple-Negative Breast Cancer Treatment Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Triple-Negative Breast Cancer Treatment Market Share (2019-2020)
Table 73. Central & South America Triple-Negative Breast Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Triple-Negative Breast Cancer Treatment Market Share by Type (2015-2020)
Table 75. Central & South America Triple-Negative Breast Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Triple-Negative Breast Cancer Treatment Market Share by Application (2015-2020)
Table 77. Celgene Company Details
Table 78. Celgene Business Overview
Table 79. Celgene Product
Table 80. Celgene Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020) (Million US$)
Table 81. Celgene Recent Development
Table 82. Roche Company Details
Table 83. Roche Business Overview
Table 84. Roche Product
Table 85. Roche Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020) (Million US$)
Table 86. Roche Recent Development
Table 87. Immunomedics GmbH Company Details
Table 88. Immunomedics GmbH Business Overview
Table 89. Immunomedics GmbH Product
Table 90. Immunomedics GmbH Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020) (Million US$)
Table 91. Immunomedics GmbH Recent Development
Table 92. Merck & Co., Inc. Company Details
Table 93. Merck & Co., Inc. Business Overview
Table 94. Merck & Co., Inc. Product
Table 95. Merck & Co., Inc. Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020) (Million US$)
Table 96. Merck & Co., Inc. Recent Development
Table 97. F. Hoffmann-La Roche Ltd Company Details
Table 98. F. Hoffmann-La Roche Ltd Business Overview
Table 99. F. Hoffmann-La Roche Ltd Product
Table 100. F. Hoffmann-La Roche Ltd Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020) (Million US$)
Table 101. F. Hoffmann-La Roche Ltd Recent Development
Table 102. Eisai Co., Ltd Company Details
Table 103. Eisai Co., Ltd Business Overview
Table 104. Eisai Co., Ltd Product
Table 105. Eisai Co., Ltd Revenue in Triple-Negative Breast Cancer Treatment Business (2015-2020) (Million US$)
Table 106. Eisai Co., Ltd Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Triple-Negative Breast Cancer Treatment Market Share by Type: 2020 VS 2026
Figure 2. Alkylating Agents Features
Figure 3. Plant Products Features
Figure 4. Microorganism Products Features
Figure 5. Antimetabolites Features
Figure 6. Microtubule Stablizing Agents Features
Figure 7. Global Triple-Negative Breast Cancer Treatment Market Share by Application: 2020 VS 2026
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Triple-Negative Breast Cancer Treatment Report Years Considered
Figure 11. Global Triple-Negative Breast Cancer Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Triple-Negative Breast Cancer Treatment Market Share by Regions: 2020 VS 2026
Figure 13. Global Triple-Negative Breast Cancer Treatment Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Triple-Negative Breast Cancer Treatment Market Share by Players in 2019
Figure 16. Global Top Triple-Negative Breast Cancer Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Triple-Negative Breast Cancer Treatment as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Triple-Negative Breast Cancer Treatment Revenue in 2019
Figure 18. North America Triple-Negative Breast Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Triple-Negative Breast Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Triple-Negative Breast Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Triple-Negative Breast Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Triple-Negative Breast Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Triple-Negative Breast Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Triple-Negative Breast Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed

以下、関連資料のご紹介

HER2陰性乳がん治療の世界市場（～2026年）

Global HER2-negative breast cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12176 2020年11月25日 97Pages
当調査資料はHER2陰性乳がん治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、手術、放射線、ホルモン療法/内分泌療法）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国...

乳癌治療の世界市場（～2026年）

Global Breast Cancer Therapeutic Market Size, Status and Forecast 2020-2026
MRC2-11QY11194 2020年11月25日 96Pages
当調査資料は乳癌治療のグローバル市場について調査・分析したレポートです。種類別（フェーズI治療、フェーズII治療、フェーズIII治療）市場規模、用途別（病院、外来手術センター、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、...

乳癌リキッドバイオプシーの世界市場（～2026年）

Global Breast Cancer Liquid Biopsy Market Size, Status and Forecast 2020-2026
MRC2-11QY11191 2020年11月25日 99Pages
当調査資料は乳癌リキッドバイオプシーのグローバル市場について調査・分析したレポートです。種類別（循環腫瘍細胞（CTC）、無細胞DNA（CfDNA）、細胞外小胞（EV）、その他循環バイオマーカー）市場規模、用途別（病院、診断センター、研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フ...

転移性がん治療の世界市場（～2026年）

Global Metastatic Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12665 2020年11月25日 91Pages
当調査資料は転移性がん治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、放射線療法、生物学的標的療法、乳腺手術、ホルモン療法）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日...

乳癌モノクローナル抗体の世界市場（～2026年）

Global Breast Cancer Monoclonal Antibodies Market Size, Status and Forecast 2020-2026
MRC2-11QY11192 2020年11月25日 125Pages
当調査資料は乳癌モノクローナル抗体のグローバル市場について調査・分析したレポートです。種類別（ネイキッドMAb、コンジュゲートMAb）市場規模、用途別（病院、小売薬局、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、イ...

転移性膵臓がん治療の世界市場（～2026年）

Global Metastatic Pancreatic Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12667 2020年11月25日 99Pages
当調査資料は転移性膵臓がん治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、標的療法、その他）市場規模、用途別（外分泌、内分泌）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台...

乳癌スクリーニング検査の世界市場（～2026年）

Global Breast Cancer Screening Tests Market Size, Status and Forecast 2020-2026
MRC2-11QY11193 2020年11月25日 92Pages
当調査資料は乳癌スクリーニング検査のグローバル市場について調査・分析したレポートです。種類別（身体検査、実験室検査、画像検査、遺伝子検査）市場規模、用途別（研究所、癌研究所、診断センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、...

非血液がん治療の世界市場（～2026年）

Global Non-Hematological Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04000 2020年11月20日 97Pages
当調査資料は非血液がん治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、手術、放射線療法、その他）市場規模、用途別（病院、腫瘍治療センター、外来手術センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、...

口腔がん治療の世界市場（～2026年）

Global Oral Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04078 2020年11月20日 98Pages
当調査資料は口腔がん治療のグローバル市場について調査・分析したレポートです。種類別（扁平上皮がん、疣贅がん、小唾液腺がん、リンパ腫）市場規模、用途別（病院・診療所、研究機関、学術機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、...

非黒色腫皮膚がん治療の世界市場（～2026年）

Global Non-Melanoma Skin Cancer Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04008 2020年11月20日 132Pages
当調査資料は非黒色腫皮膚がん治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、放射線療法、光線力学療法）市場規模、用途別（病院、診療所、外来外科センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国...

HER2陰性乳がん治療の世界市場（～2026年） HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein. Market Analysis and Insights: Global HER2-negative breast ca…
乳癌治療の世界市場（～2026年） Market Analysis and Insights: Global Breast Cancer Therapeutic Market The global Breast Cancer Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Breast Cancer Therapeutic Scope and Market Size Breast Cancer T…
乳癌スクリーニング検査の世界市場（～2026年） Breast cancer is usually a form of tumor that can be visualized through x-ray or felt as a lump. The cancer can be either benign which results in the abnormal growth in the breast area or metastatic that can invade the distant areas of the body. Breast cancer screening is conducted to detect the sig…
乳癌リキッドバイオプシーの世界市場（～2026年） Breast Cancer Liquid Biopsy can be usually used in breast biopsy, based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. Market Analysis and Insights: Global Breast Cancer …
乳癌モノクローナル抗体の世界市場（～2026年） Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protei…